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Lower extremity artery disease [peripheral artery dis-
ease (PAD)] is a highly prevalent disease estimated to 
affect over 200 million people worldwide.1 Its presence 
increases the risk of mortality, intermittent claudication 
and tissue loss.2 Patients with concomitant diabetes 
mellitus are considered particularly vulnerable as they 
carry a particular poorer prognosis than those with 
either disease alone.3
Treatment guidelines for claudicants recommend 
supervised exercise training as first-line therapy;2 how-
ever, this comes with a number of barriers particularly in 
the elderly population.4 Motivation to exercise, osteoar-
thritis, psychosocial factors, congestive heart failure or 
chronic obstructive pulmonary disease may be preclude 
adherence to any form of active exercise therapy.
In this context, electrical stimulation (ES) technology is 
being proposed as a potential alternative or adjunct to tra-
ditional exercise to improve claudication symptoms in a 
target PAD and diabetes population.
A prospective, one-group, pretest–posttest study 
design was conducted subsequent to University Research 
Ethics Committee approval. Consenting participants 
were assessed for eligibility after being randomly selected 
from a hospital database of patients with type 2 diabetes 
and symptomatic PAD. Inclusion criteria included the 
following: PAD defined with an ankle-brachial index 
(ABI) < 0.9, abnormal spectral waveforms on the ankle 
arteries of both limbs and calf-muscle intermittent clau-
dication, reproducible on a graded treadmill test.
Exclusion criteria included: Change in cardiovascular 
medication within the past year or during the intervention, 
history of renal disease or spinal stenosis, medial artery 
calcification (ABI > 1.3), sensory or autonomic neuropathy, 
previous foot/toe amputations or history of oral claudica-
tion therapy.
To quantify claudication severity and response to treat-
ment, the graded treadmill protocol was utilized as a serial 
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measure to acquire the absolute claudication distance 
(ACD), defined as the distance at which claudication 
becomes severe so that the participant is forced to stop.5 
The treadmill was initiated and maintained at a fixed speed 
of 3.2 km/h while the slope was increased by 2° every 
2 min up to a maximum of 10° from an initial inclination 
of 0°. The recorded distance was not disclosed to the 
participant to ensure blinding.
The ES device (Veinoplus® Arterial Model 2.1; Ad 
Rem Technology, France) was given to each participant 
for home use following a demonstration session. It con-
sisted of a central unit with two adhesive electrodes 
designed to be attached transcutaneously on the calf mus-
cle, generating ES at varying frequencies (1–250 Hz) 
through a series of rectangular pulses of low energy 
(<25 uC) and low voltage (50 V peak) within a fixed 1-h 
session. Subsequently, this was applied for 1 h every day 
for a period of 12 weeks.
The Wilcoxon signed rank test was used to evaluate the 
significant difference in mean ACD since the Kolmogorov–
Smirnov test revealed a non-normal distribution of base-
line and follow-up data sets.
From a total of 81 prospective participants, 40 partici-
pants [30 males; mean age = 71 years, standard deviation 
(SD) = 7; body mass index = (BMI) 28.8; SD = 3.7; 
mean ankle-brachial pressure index (ABPI) = 0.70, 
SD = 0.12; mean diabetes duration = 15 years, SD = 6; 
mean HbA1c = 8.22, SD = 1.56; 32.5% active smokers] 
satisfied the inclusion criteria and were recruited.
At baseline, the recorded mean ACD was 333.71 m 
(SD = 208). Following a mean intervention period of 
91.68 (SD = 6.23) consecutive days, the mean ACD was 
470.7 m (SD = 279). This translated to a mean improve-
ment in the ACD of 137 m (SD = 136) reflecting an 
improvement in maximum walking capacity of 41% 
relative to baseline. Utilizing the Wilcoxon signed rank 
test, this improvement was found to be statistically sig-
nificant (p = 0.000).
Findings of this study confirm a significant mean 
increase (p = 0.000) in ACD of 137 m following 91.68 days 
(SD = 6.23) of 1 h ES of the calf muscles. The novelty of 
this study is that it is the largest study stimulating ischae-
mic limbs (N = 80), for the longest intervention period to 
date (12 weeks), utilizing an ES device of varying frequen-
cies in contrast to previous studies.6,7
The effects of ES on ischaemic muscles may include 
the augmentation of angiogenesis and morphological 
muscular adaptation.8–10 It has been demonstrated that 
ES augments the endogenous production of vascular 
growth factors, thus facilitating angiogenesis in ischae-
mic muscle.8 New capillaries increase blood flow and 
oxygen availability to the exercising muscle, lessening 
the ischaemic symptoms.9 Additionally, muscle fibre 
activation is enhanced by ES, while selective recruit-
ment of fatigue-resistant type 1 muscle fibres is also 
thought to contribute to the improvement in claudica-
tion symptoms.10
These results provide new insights on ES while 
opening up new treatment options for the claudicant 
population. Furthermore, the ability of ES to produce 
muscular exercise activity without gross movement of 
joints or whole body exercise is an added advantage 
particularly in patients with comorbid disease such as 
severe osteoarthritis, chronic heart failure or pulmonary 
diseases.
Given the positive results, future research constituting 
randomized controlled trials with a larger sample size are 
indicated. In this study, this was not possible due to limited 
number of eligible participants available. By evaluating 
the macro-circulatory response to ES, future studies may 
also reveal whether the effectiveness of ES may extend 
beyond reduction in claudication symptoms.
In conclusion, electrical calf-muscle stimulation signifi-
cantly increased the walking capacity in claudicants living 
with type 2 diabetes. While urging further research in this 
field, this study signifies positive prospects for ES as an 
adjunct treatment modality for claudication symptoms par-
ticularly in those precluded from active exercise training.
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